Comparative Pharmacology
Head-to-head clinical analysis: HYDRO D versus NAQUA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO D versus NAQUA.
HYDRO-D vs NAQUA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, reducing sodium and water reabsorption and increasing potassium excretion.
Inhibition of sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis.
25-100 mg orally once daily in the morning.
Oral: 5-10 mg once daily, preferably in the morning. Maximum dose 20 mg/day.
None Documented
None Documented
Terminal elimination half-life: 5.6 to 15 hours; prolonged in renal impairment and in patients with heart failure.
Terminal elimination half-life is 6-12 hours; prolonged in renal impairment (up to 20-30 hours) or heart failure due to reduced renal perfusion.
Renal: approximately 50% as unchanged drug; biliary/fecal: approximately 50% as metabolites and minor unchanged drug.
Primarily renal elimination; approximately 60-80% excreted unchanged in urine via tubular secretion; minor biliary/fecal excretion (<10%).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic